Stay updated with breaking news from Mutation Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease
Investegate announcements from AstraZeneca PLC, Tagrisso approved in Japan for early lung cancer
Investegate announcements from Hutchmed China Ltd, Preliminary results from SAVANNAH Phase 2 Trial
07.03.2022 - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) - (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) ...
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of...